New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Key Takeaways Eli Lilly reported a late-stage study of its oral weight-loss pill met primary and key secondary endpoints.The ...

Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

On the charts, LLY has been climbing since its August 8th 52-week low of $623.78, heading for its 10th gain in the last 12 ...

In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

The results of the ATTAIN-2 study, which involved people with obesity or overweight and type 2 diabetes, showed that the oral ...

After Eli Lilly’s phase 3 data drop for its oral GLP-1 asset orforglipron earlier this month, the Indianapolis drugmaker has unveiled the second half of the data package that will support the med’s | ...

FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Using the Mediterranean diet, exercise and nutritional support, severely overweight people stopped their progression to type ...